EUR 50 million for social businesses - Boehringer Ingelheim launches Boehringer Ingelheim Social Engagements

Boehringer IngelheimBoehringer Ingelheim announced that it will dedicate EUR 50 million to a new initiative called "Boehringer Ingelheim Social Engagements". The program provides financing for impact to social businesses in vulnerable communities through non-traditional financing options, combined with a partnering approach.

"Start-ups often need more than just funding, so we aim to provide financial and non-financial support together with complementary partners. Boehringer Ingelheim Social Engagements is dedicating 50 million Euros to help scale up solutions of social businesses to create systemic change," says Michael Schmelmer, Member of the Board of Managing Directors at Boehringer Ingelheim, announcing the initiative on the occasion of the "Making More Health Together 2021" convention.

Boehringer Ingelheim Social Engagements is an extension of Boehringer Ingelheim's flagship initiative, Making More Health (MMH). MMH was jointly created by Boehringer Ingelheim and Ashoka, the world's largest network of social entrepreneurs. This long-term partnership focuses on connecting innovative solutions with business expertise to address complex healthcare challenges for people, animals, and their communities.

One initiative is the Making More Health Business Accelerator, a program targeted towards social entrepreneurs in Sub-Saharan Africa. Since 2018, it provides financial means, in form of donations, and business expertise support through Boehringer Ingelheim employee engagement. Until today, 12 social businesses have been supported, and many have progressed to a stage, where more substantial funding is necessary. Boehringer Ingelheim Social Engagements is now stepping up to provide financial support beyond typical corporate donations. With this, Boehringer Ingelheim also wants to enable additional funding from other investors and engage with likeminded partners to catalyze expertise. This closes a critical financing gap for these social businesses.

After an initial start-up phase in 2022, Boehringer Ingelheim Social Engagements will extend its focus beyond the Making More Health Business Accelerator in Sub-Sahara Africa, by targeting additional projects globally.

Making More Health has committed to positively impact the lives and health of 50 million people and engage 20,000 Boehringer Ingelheim employees by 2030. Boehringer Ingelheim Social Engagements will be key to achieving this objective. An overview with case studies on the Making More Health Accelerator, as well as local projects can be found here.

About Making More Health

Making More Health (MMH) is a long-term global initiative of Boehringer Ingelheim in collaboration with Ashoka, the world-largest network of social entrepreneurs. It focuses on co-creation with the aim of creating shared value to achieve better solutions for today's global challenges, by integrating innovative social entrepreneurial thinking into business practices. MMH provides sustainable and holistic solutions to communities worldwide since 2010. Learn more at www.makingmorehealth.com

About Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

Most Popular Now

Findings open way for personalised MS treatment

Currently available therapies to treat multiple sclerosis (MS) lack precision and can lead to serious side effects. Researchers at Karolinska Institutet in Sweden have no...

Pfizer shares top-line results from Phase 2/3 EPIC…

Pfizer Inc. (NYSE: PFE) shared top-line results from the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study evaluating...

Pfizer and Biohaven's VYDURA® (rimegepant) granted…

Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorizatio...

A smarter way to develop new drugs

Pharmaceutical companies are using artificial intelligence to streamline the process of discovering new medicines. Machine-learning models can propose new molecules that ...

Cognitive impairment from severe COVID-19 equivale…

Cognitive impairment as a result of severe COVID-19 is similar to that sustained between 50 and 70 years of age and is the equivalent to losing 10 IQ points, say a team o...

Foundation S: Sanofi's new philanthropic spearhead

Sanofi today launches Foundation S - The Sanofi Collective, its philanthropic endowment fund aiming to create healthier futures for generations. Using donations, partners...

SK bioscience and GSK's adjuvanted COVID-19 vaccin…

SK bioscience and GSK announced submission of a biologics license application for SKYCovione™ a recombinant protein-based COVID-19 vaccine candidate adjuvanted with GSK’s...

Investigational COVID mucosal vaccine protects aga…

In animal studies that mimic human exposures, an investigational COVID vaccine designed to be taken orally not only protects the host, but also decreases the airborne spr...

Using AI to analyze large amounts of biological da…

Researchers at the University of Missouri are applying a form of artificial intelligence (AI) - previously used to analyze how National Basketball Association (NBA) playe...

Asthma drug can block crucial SARS-CoV-2 protein

A drug used to treat asthma and allergies can bind to and block a crucial protein produced by the virus SARS-CoV-2, and reduce viral replication in human immune cells, ac...

Recurring brain tumor growth is halted with new dr…

When a non-metastatic brain tumor - a meningioma - recurs after surgery and radiation treatment, a patient is out of options. No drugs are approved for these aggressive t...

Pfizer to acquire Biohaven Pharmaceuticals

Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) have entered into a definitive agreement under which Pfizer will acquire Biohaven, t...